<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02740582</url>
  </required_header>
  <id_info>
    <org_study_id>Tolcapone Lab Bar</org_study_id>
    <nct_id>NCT02740582</nct_id>
  </id_info>
  <brief_title>Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users</brief_title>
  <official_title>Effects of Tolcapone on Decision Making and Alcohol Intake Using a Laboratory Bar in Moderate to Heavy Social Drinkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jennifer Mitchell</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of tolcapone on decision making and&#xD;
      alcohol intake using a laboratory bar (on-site alcohol self-administration) in alcohol&#xD;
      drinkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a 7-session, double blind, placebo-controlled crossover study of the effects of&#xD;
      tolcapone, the COMT inhibitor, on decision making and alcohol intake using a laboratory bar&#xD;
      in moderate to heavy social alcohol drinkers. Subjects will be moderate to heavy social users&#xD;
      of alcohol, defined as at least 10 standard drinks per week for women and at least 14&#xD;
      standard drinks per week for men. There will be one screening session followed by six&#xD;
      additional visits including 2 laboratory bar sessions. On each study drug administration day,&#xD;
      subjects will come in to the clinic for a medication dispensation visit and instructions on&#xD;
      when and how to take the study drug for the remainder of the study. Study drug bottles will&#xD;
      be equipped with MEMS caps to ensure compliance. After 5 days of drug administration,&#xD;
      subjects will return to the clinic for a laboratory bar. This session will consist of&#xD;
      administration of a standardized laboratory bar paradigm and a series of computerized and&#xD;
      written decision-making tasks. Subjects will then be crossed over and complete the same&#xD;
      series of study visits on the alternate study drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">November 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Drinks Consumed in a Laboratory Bar Session</measure>
    <time_frame>A laboratory bar session is 1 hour long</time_frame>
    <description>Number of drinks consumed in a laboratory bar session (out of a maximum of 4 drinks available) following either placebo or tolcapone administration.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Alcohol Abuse</condition>
  <condition>Impulsive Behavior</condition>
  <arm_group>
    <arm_group_label>Tolcapone First, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tolcapone arm first: 5 days of 100 mg tolcapone TID, followed by washout period, then 5 days of placebo TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo First, then Tolcapone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm first: 5 days placebo, followed by washout period, followed by 5 days of 100 mg tolcapone TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolcapone</intervention_name>
    <arm_group_label>Placebo First, then Tolcapone</arm_group_label>
    <arm_group_label>Tolcapone First, then Placebo</arm_group_label>
    <other_name>Tasmar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo First, then Tolcapone</arm_group_label>
    <arm_group_label>Tolcapone First, then Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers who are 21-40 years of age&#xD;
&#xD;
          -  If female, 10 or more alcoholic drinks must be consumed weekly.&#xD;
&#xD;
          -  If male, 14 or more alcoholic drinks must be consumed weekly.&#xD;
&#xD;
          -  Meets DSM-V criteria for Alcohol Use Disorder (AUD).&#xD;
&#xD;
          -  If female, must be non-lactating, not pregnant, and using a reliable contraception&#xD;
             method (i.e. abstinence, intrauterine device [IUD], hormonal birth control, or barrier&#xD;
             method).&#xD;
&#xD;
          -  Ability to read and speak English.&#xD;
&#xD;
          -  High school graduate.&#xD;
&#xD;
          -  Able and willing to provide an informed consent.&#xD;
&#xD;
          -  Able to understand and follow the instructions of the investigator, including the&#xD;
             delayed discounting tasks. Residing within 5 miles of the study site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive urine drug screen (except marijuana).&#xD;
&#xD;
          -  Using cocaine, stimulants (other than nicotine and caffeine), amphetamines,&#xD;
             hallucinogens, ecstasy, opiates, sedatives, pain pills, sleeping pills. or other&#xD;
             psychoactive drugs within 2 weeks of the start of the study (except marijuana).&#xD;
&#xD;
          -  Marijuana use more than 3 times/week.&#xD;
&#xD;
          -  Current enrollment in an alcohol, or other drug treatment program or current legal&#xD;
             problems relating to alcohol, or other drug use.&#xD;
&#xD;
          -  Currently trying to quit alcohol use.&#xD;
&#xD;
          -  History of major alcohol related complications within the preceding 2 years (liver&#xD;
             failure/cirrhosis, pancreatitis, esophageal varices, etc.).&#xD;
&#xD;
          -  Two SGPT/ALT or SGOT/AST values greater than the upper limit of normal.&#xD;
&#xD;
          -  Unable to pass the Standard Field Sobriety Test in a sober state (BAC = 0.00).&#xD;
&#xD;
          -  BAC level &gt;0.05% at the beginning of screening visit (within margin of error of&#xD;
             detection).&#xD;
&#xD;
          -  Regular use of any of the drugs on the tolcapone contraindications list OR within 2&#xD;
             weeks of drug administration.&#xD;
&#xD;
          -  Severe low blood (&lt; 90/50) pressure or uncontrolled high blood pressure (&gt;160/100).&#xD;
             Allergy or intolerance to tolcapone.&#xD;
&#xD;
          -  Subject has received an investigational drug within 30 days of the screening visit.&#xD;
&#xD;
          -  Subject is considered unsuitable for the study in the opinion of the investigator or&#xD;
             clinician for any other reason (such as an Axis II personality disorder that makes the&#xD;
             subject unable to comply with study instructions, per the Clinician's judgement.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Mitchell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Berkeley</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Coker AR, Weinstein DN, Vega TA, Miller CS, Kayser AS, Mitchell JM. The catechol-O-methyltransferase inhibitor tolcapone modulates alcohol consumption and impulsive choice in alcohol use disorder. Psychopharmacology (Berl). 2020 Oct;237(10):3139-3148. doi: 10.1007/s00213-020-05599-5. Epub 2020 Jul 2.</citation>
    <PMID>32617646</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <results_first_submitted>August 12, 2020</results_first_submitted>
  <results_first_submitted_qc>September 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2020</results_first_posted>
  <last_update_submitted>September 17, 2020</last_update_submitted>
  <last_update_submitted_qc>September 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Jennifer Mitchell</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Impulsive Behavior</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolcapone</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT02740582/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tolcapone First</title>
          <description>Tolcapone arm first: 5 days of 100 mg tolcapone TID, followed by washout period, then 5 days of placebo TID</description>
        </group>
        <group group_id="P2">
          <title>Placebo First</title>
          <description>Placebo arm first: 5 days placebo, followed by washout period, followed by 5 days of 100 mg tolcapone TID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Completers of study were used for analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Tolcapone First</title>
          <description>Tolcapone arm first: 5 days of 100 mg tolcapone TID, followed by washout period, then 5 days of placebo TID&#xD;
Tolcapone&#xD;
Placebo</description>
        </group>
        <group group_id="B2">
          <title>Placebo First</title>
          <description>Placebo arm first: 5 days placebo, followed by washout period, followed by 5 days of 100 mg tolcapone TID&#xD;
Tolcapone&#xD;
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.4" lower_limit="21" upper_limit="32"/>
                    <measurement group_id="B2" value="27.3" lower_limit="21" upper_limit="35"/>
                    <measurement group_id="B3" value="25.98" lower_limit="21" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Self-reported alcoholic drinks / week</title>
          <units>alcoholic drinks / week</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.79" lower_limit="10" upper_limit="52"/>
                    <measurement group_id="B2" value="18.13" lower_limit="10" upper_limit="49.5"/>
                    <measurement group_id="B3" value="21.13" lower_limit="10" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Drinks Consumed in a Laboratory Bar Session</title>
        <description>Number of drinks consumed in a laboratory bar session (out of a maximum of 4 drinks available) following either placebo or tolcapone administration.</description>
        <time_frame>A laboratory bar session is 1 hour long</time_frame>
        <population>Completers were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Tolcapone First, Then Placebo</title>
            <description>Tolcapone arm first: 5 days of 100 mg tolcapone TID, followed by washout period, then 5 days of placebo TID&#xD;
Tolcapone&#xD;
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then Tolcapone</title>
            <description>Placebo arm first: 5 days placebo, followed by washout period, followed by 5 days of 100 mg tolcapone TID&#xD;
Tolcapone&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Drinks Consumed in a Laboratory Bar Session</title>
          <description>Number of drinks consumed in a laboratory bar session (out of a maximum of 4 drinks available) following either placebo or tolcapone administration.</description>
          <population>Completers were analyzed</population>
          <units>drinks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Drinks on Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="1.45"/>
                    <measurement group_id="O2" value="2.96" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks on tolcapone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="1.38"/>
                    <measurement group_id="O2" value="2.39" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment through study completion, an average of 3 weeks</time_frame>
      <desc>The study staff will probe, via effects scale survey completed by subjects and discussion with the subject where necessary, for the occurrence of AEs during each subject visit. Study staff will continue to follow up with the subject daily until the matter is resolved (AE has decreased to 2).</desc>
      <group_list>
        <group group_id="E1">
          <title>Tolcapone</title>
          <description>Adverse Events Groups are being reported &quot;per intervention&quot; (e.g., &quot;Tolcapone&quot; and &quot;Placebo&quot;) rather than based on group in the cross over study. Tolcapone Group here reflect all participants who received Tolcapone during the study, regardless of order.</description>
        </group>
        <group group_id="E2">
          <title>Placebeo</title>
          <description>Adverse Events Groups are being reported &quot;per intervention&quot; (e.g., &quot;Tolcapone&quot; and &quot;Placebo&quot;) rather than based on group in the cross over study. Placebo Group here reflect all participants who received Placebo during the study, regardless of order.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Mitchell, PhD</name_or_title>
      <organization>University of California, San Franciso</organization>
      <phone>510-985-3522</phone>
      <email>jennifer.mitchell@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

